Description
World Market for Precision Cancer Diagnostic Tests
Precision cancer tests encompass imaging and in vitro diagnostic (IVD) products and procedures that directly detect malignancies in patient samples or in the patients themselves. These tests are also used in cancer staging as well as in the selection, monitoring, and assessment of prescribed oncological therapies. World Market for Precision Cancer Diagnostic Tests, a market-based and industry-focused report, examines the global market environment for precision cancer testing products and procedures, including the following data:
- Market for Precision Cancer Testing, IVD and Imaging, 2018-2023
- Global Precision Cancer Diagnostic Testing Product Demand by Type & Geographical Market, 2018-2023 (Imaging, Molecular, Histology/Cytology, Tumor Marker Immunoassays, POC Colon Cancer Tests, Total; United States, Canada, Western Europe, Australia, Japan, South Korea, Total Developed Economies; Total Developing Economies) (million dollars)
- Precision Cancer Diagnostic Testing Procedural Volume by Type, 2018-2023 (Imaging, Molecular, Histology/Cytology, Tumor Marker Immunoassays, POC Colon Cancer Tests, Total) (in millions)
- Global Precision Cancer Diagnostic Testing Procedures by Type, 2018-2023 (Imaging, Molecular, Histology/Cytology, Tumor Marker Immunoassays, POC Colon Cancer Tests, Average) ($ product/test)
Procedures & Products
The volume of precision cancer related procedures is projected to rise. Several trends and factors will influence growth. Advances in imaging and molecular technologies will lead to the introduction of new tests with enhanced tumor specificity and sensitivity. The upgrading and modernization of medical delivery systems in many countries will make more funding available for cancer care. An increasing emphasis on preventive medicine in global healthcare will boost demand for tests that enable the early detection of tumors. The report examines cancer imaging and types of cancer testing including in situ hybridization, blood-based molecular cancer tests, HPV genotyping, mass spectrometry (MS) tests, next-generation sequencing tests, circulating tumor cell (CTC) tests, pharmacodiagnostic tests, microarray tests, histology/cytology cancer tests, Pap tests, immunohistochemistry tests, flow cytometry tests, tumor marker immunoassays and point of care colorectal cancer tests, providing the following market data points:
- Global Precision Cancer Diagnostic Procedural Volume, 2018-2023 (Imaging Tests, Molecular Tests, Histology/Cytology Tests, Tumor Marker Immunoassays, POC Colorectal Cancer Tests, Total) (million)
- Global Precision Cancer Diagnostic Product Demand, 2018-2023 (Imaging Tests, Molecular Tests, Histology/Cytology Tests, Tumor Marker Immunoassays, POC Colorectal Cancer Tests, Total) (million US dollars)
- Global Cancer Imaging Procedural Volume, 2018-2023 (Ultrasound, Computed Tomography, Magnetic Resonance Imaging, Digital Mammography, Positron Emission Tomography, Analog Mammography, Digital Breast Tomosynthesis, Molecular Breast Imaging, Other Imaging, Total) (million)
- Global Cancer Imaging Product Demand, 2018-2023 (Ultrasound, Computed Tomography, Magnetic Resonance Imaging, Digital Mammography, Positron Emission Tomography, Analog Mammography, Digital Breast Tomosynthesis, Molecular Breast Imaging, Other Imaging, Total) (million US dollars)
- Global Molecular Cancer Testing Procedural Volume, 2018-2023 (In Situ Hybridization Tests, Blood-Based Tests, HPV Genotyping Procedures, Next-Generation Sequencing Tests, Mass Spectrometry Tests, Circulating Tumor Cell Tests, Pharmacodiagnostic Tests, Microarray Tests, Total) (million)
- Global Molecular Cancer Testing Product Demand, 2018-2023 (In Situ Hybridization Tests, Blood-Based Tests, HPV Genotyping Procedures, Next-Generation Sequencing Tests, Mass Spectrometry Tests, Circulating Tumor Cell Tests, Pharmacodiagnostic Tests, Microarray Tests, Total) (million US dollars)
- Global In Situ Hybridization (ISH) Cancer Testing Procedural Volume & Product Demand, 2018-2023
- Global Blood-Based Molecular Cancer Testing Procedural Volume & Product Demand, 2018-2023
- Global HPV Genotyping Cancer Testing Procedural Volume & Product Demand, 2018-2023
- Global Next-Generation Sequencing (NGS) Cancer Testing Procedural Volume & Product Demand, 2018-2023
- Global Mass Spectrometry (MS) Cancer Testing Procedural Volume & Product Demand, 2018-2023
- Selected Mass Spectrometry-Based Oncology Tests
- Global Circulating Tumor Cell Cancer Testing Procedural Volume & Product Demand, 2018-2023
- Global Pharmacodiagnostic (PCD) Cancer Testing Procedural Volume & Product Demand, 2018-2023
- Global Microarray Cancer Testing Procedural Volume & Product Demand, 2018-2023
- Global Histology/Cytology Cancer Testing Procedural Volume, 2018-2023 (Pap Tests, Immunohistochemistry Tests, Flow Cytometry Tests, Other Histology/Cytology Tests, Total) (million)
- Global Histology/Cytology Cancer Testing Product Demand, 2018-2023 (Pap Tests, Immunohistochemistry Tests, Flow Cytometry Tests, Other Histology/Cytology Tests, Total) (million US dollars)
- Global Pap Test Procedural Volume & Product Demand, 2018-2023
- Global Immunohistochemistry (IHC) Cancer Testing Procedural Volume & Product Demand, 2018-2023
- Global Flow Cytometry Cancer Testing Procedural Volume & Product Demand, 2018-2023
- Global Other Histology/Cytology (H/C) Cancer Testing Procedural Volume & Product Demand, 2018-2023
- Global Tumor Marker Immunoassay Procedural Volume & Product Demand, 2018-2023
- Global Tumor Marker Immunoassay Product Demand by Type, 2018-2023 (Prostate Specific Antigen [PSA], CA-125, AFP, CEA, Other, Total) (million US dollars)
- Global POC Colon Cancer Testing Procedural Volume & Product Demand, 2018-2023 (Ethical Tests, Over-the-Counter Tests)
Geographic Markets
The size and growth potential of geographical markets for precision cancer diagnostic procedures and products vary widely from country to country due to differences in demographic patterns, lifestyles trends, health insurance coverage, healthcare spending intensity, medical delivery systems, patient care approaches, and price controls. Based on a high level of national health expenditures and patient activity, the US market will remain the largest and most diversified. The report surveys precision cancer testing indicators for 2018 to 2023, including new cancer cases (thousand), precision cancer diagnostic procedures (million), and precision cancer diagnostic product demand (mil US$), across the following geographic markets:
- United States
- Canada
- Mexico
- Western Europe
- France
- Germany
- Italy
- Spain
- United Kingdom
- Other Western Europe
- Asia/Pacific
- Australia
- China
- India
- Japan
- Other Asia/Pacific
- Brazil
- Other Central & South America
- Eastern Europe
- Africa/Mideast
Industry Structure
The global precision cancer diagnostics segment includes approximately 300 participants, ranging in size from small, narrowly focused firms to large, diversified multinational companies. Since precision cancer diagnostics serve health care applications, they are subject to strict government regulations and serve highly price-sensitive markets. Overall success in the industry requires an effective balancing of research and development productivity, manufacturing efficiencies, effective marketing and distribution, and responsive customer service.
World Market for Precision Cancer Diagnostic Tests explores the activities of selected companies involved in the segment to serve as a representative sample of competitors active in the business. The companies profiled in the report include the following:
- Abbott Laboratories
- Agilent Technologies, Inc.
- Angle plc
- Becton Dickinson and Company
- Bio-Rad Laboratories, Inc.
- Biocartis N.V.
- Biocept, Inc.
- bioMérieux SA
- Canon Medical Systems Corporation
- Cynvenio Biosystems, Inc.
- Danaher Corporation
- Epigenomics AG
- Exact Sciences Corporation
- Exosome Diagnostics, Inc.
- Foundation Medicine, Inc.
- General Electric Company
- Genomic Health, Inc.
- Hologic, Inc.
- Illumina, Inc.
- Menarini Silicon Biosystems SpA
- Myriad Genetics, Inc.
- NanoString Technologies, Inc.
- Ortho Clinical Diagnostics
- QIAGEN N.V.
- Randox Laboratories Ltd.
- Roche Holding AG
- Royal Philips N.V.
- Siemens AG
- Thermo Fisher Scientific
- Vela Diagnostics
Included in the demand estimates and forecasts that appear in this report are the value of reagents and other consumables employed directly in precision cancer procedures and a percentage of the value of instruments and systems purchased by end users. This percentage reflects the portion of total IVD and imaging tests that involve cancer-related applications. The analysis covers commercially sold and distributed tests only. Laboratory developed tests (LDTs) and tests used for research purposes are excluded from the discussion.
